For the quarter ending 2025-09-30, VVOS made $6,783,000 in revenue. -$5,400,000 in net income. Net profit margin of -79.61%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | 6,783,000 | 3,820,000 | 3,016,000 | 3,558,500 |
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 2,846,000 | 1,710,000 | 1,507,000 | 1,541,500 |
| Gross profit | 3,937,000 | 2,110,000 | 1,509,000 | 2,017,000 |
| General and administrative | 7,884,000 | 6,409,000 | 4,892,000 | 4,634,500 |
| Sales and marketing | 403,000 | 260,000 | 358,000 | 532,500 |
| Depreciation and amortization | 384,000 | 306,000 | 177,000 | 145,000 |
| Total operating expenses | 8,671,000 | 6,975,000 | 5,427,000 | 5,312,000 |
| Operating loss | -4,734,000 | -4,865,000 | -3,918,000 | -3,295,000 |
| Other expense | -679,000 | -163,000 | -4,000 | -35,000 |
| Other income | 13,000 | 15,000 | 58,000 | 35,000 |
| Loss before income taxes | -5,400,000 | -5,013,000 | -3,864,000 | -3,295,000 |
| Net loss | -5,400,000 | -5,013,000 | -3,864,000 | -3,295,000 |
| Net loss per share (basic) | -0.49 | -0.55 | -0.45 | -0.61 |
| Net loss per share (diluted) | -0.49 | -0.55 | -0.45 | -0.61 |
| Weighted average number of shares of common stock outstanding (basic) | 10,963,590 | 9,087,202 | 8,595,288 | -2,411,898.5 |
| Weighted average number of shares of common stock outstanding (diluted) | 10,963,590 | 9,087,202 | 8,595,288 | -2,411,898.5 |
Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. (VVOS)